These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 228890)

  • 1. Epstein--Barr virus-associated antibodies in IgG and IgA of nasopharyngeal carcinoma patients.
    Yang CS; Yang HM; Yeh YS; Lynn TC
    Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):167-75. PubMed ID: 228890
    [No Abstract]   [Full Text] [Related]  

  • 2. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value.
    Desgranges C; de-The G
    IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528
    [No Abstract]   [Full Text] [Related]  

  • 3. IgA and nasopharyngeal carcinoma.
    Desgranges C; De-The G
    IARC Sci Publ (1971); 1978; (24 Pt 2):883-91. PubMed ID: 221410
    [No Abstract]   [Full Text] [Related]  

  • 4. IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients.
    Ho HC; Ng MH; Kwan HC
    Br J Cancer; 1977 Jun; 35(6):888-90. PubMed ID: 194619
    [No Abstract]   [Full Text] [Related]  

  • 5. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.
    Ho HC; Ng MH; Kwan HC; Chau JC
    Br J Cancer; 1976 Dec; 34(6):655-60. PubMed ID: 188437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 8. Neutralizing EBV-specific IgA in throat washings of nasopharyngeal carcinoma (NPC) patients.
    Desgranges C; De-Thé G; Ho JH; Ellouz R
    Int J Cancer; 1977 May; 19(5):627-33. PubMed ID: 193801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals.
    Zhu XX; Zeng Y; Wolf H
    Int J Cancer; 1986 May; 37(5):689-91. PubMed ID: 3009331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
    Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [IgG and IgA antibodies to the Epstein-Barr virus and nasopharyngeal carcinoma].
    Vera Sempere FJ
    Med Clin (Barc); 1992 May; 98(19):758-9. PubMed ID: 1318986
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
    Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma.
    Foong YT; Cheng HM; Sam CK; Dillner J; Hinderer W; Prasad U
    Int J Cancer; 1990 Jun; 45(6):1061-4. PubMed ID: 1693600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBV specific secretory IgA in saliva of NPC patients. Presence of secretory piece in epithelial malignant cells.
    Desgranges C; Li JY; De-Thé
    Int J Cancer; 1977 Dec; 20(6):881-6. PubMed ID: 201574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus specific antibodies in patients with IgA nephropathy.
    Wu AY; Lau YK; Chia KB; Lim CH
    Singapore Med J; 1988 Jun; 29(3):257-60. PubMed ID: 2847323
    [No Abstract]   [Full Text] [Related]  

  • 17. Epstein-Barr virus specific IgA serum antibodies in nasopharyngeal and other respiratory carcinomas.
    Desgranges C; de-Thé G
    Int J Cancer; 1979 Nov; 24(5):555-9. PubMed ID: 231014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
    Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
    J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.